Research graph
References from Evaluating Interim Progression: First Posttherapy 177 Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1056/nejmoa2107322
10.1056/nejmoa2107322 · External reference
177Lu–prostate-specific membrane antigen radioligand therapy in patients with metastatic castration-resistant prostate cancer
10.1148/radiol.220859 · 2023 · External reference
10.1016/j.ejca.2016.03.082
10.1016/j.ejca.2016.03.082 · External reference
Considerations on integrating prostate-specific membrane antigen positron emission tomography imaging into clinical prostate cancer trials by National Clinical Trials Network cooperative groups
10.1200/jco.21.02440 · 2022 · External reference
10.2967/jnumed.123.267234
10.2967/jnumed.123.267234 · External reference
In comparison to PSA, interim Ga-68-PSMA PET/CT response evaluation based on modified RECIST 1.1 after 2nd cycle is better predictor of overall survival of prostate cancer patients treated with 177Lu-PSMA
10.3389/fonc.2021.578093 · 2021 · External reference
10.2967/jnumed.119.233817
10.2967/jnumed.119.233817 · External reference
10.2967/jnumed.124.268071
10.2967/jnumed.124.268071 · External reference
Measuring response in metastatic castration-resistant prostate cancer using PSMA PET/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria
10.1007/s00259-022-05882-x · 2022 · External reference
10.2967/jnumed.123.265952
10.2967/jnumed.123.265952 · External reference
10.2967/jnumed.125.270979
10.2967/jnumed.125.270979 · External reference
Response evaluation criteria in PSMA PET/CT (RECIP 1.0) in metastatic castration-resistant prostate cancer
10.1148/radiol.222148 · 2023 · External reference
10.1001/jama.281.17.1591
10.1001/jama.281.17.1591 · External reference
10.1001/jama.294.4.433
10.1001/jama.294.4.433 · External reference
10.1001/jama.1992.03480160073037
10.1001/jama.1992.03480160073037 · External reference
PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis
10.1007/s00259-020-05040-1 · 2021 · External reference
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617
10.1007/s00259-020-04723-z · 2020 · External reference
Trial design and objectives for patients with prostate cancer: recommendations from the Prostate Cancer Working Group 4
10.1200/jco-25-02834 · 2026 · External reference
[177Lu]Lu-PSMA SPECT/CT for early response assessment using quantitative RECIP 1.0
10.1007/s00259-025-07613-4 · 2026 · External reference
